UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

BMC cancer, 2022-08, Vol.22 (1), p.1-901, Article 901

2022

Volltextzugriff (PDF)

Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease

Current topics in medicinal chemistry, 2009-05, Vol.9 (7), p.599-610

2009

Volltextzugriff (PDF)

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Blood cancer journal (New York), 2024-07, Vol.14 (1), p.107-10, Article 107

2024

Volltextzugriff (PDF)

Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors

Bioorganic & medicinal chemistry letters, 2016-09, Vol.26 (17), p.4216-4222

2016

Volltextzugriff (PDF)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.63-63, Article 63

2022

Volltextzugriff (PDF)

RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation

Journal of the American Society of Nephrology, 2005-07, Vol.16 (7), p.1977-1984

2005

Volltextzugriff (PDF)

Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation

Journal of the American Society of Nephrology, 2004, Vol.15 (1), p.21-32

2004

Volltextzugriff (PDF)

Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8039-8039

2022

Volltextzugriff (PDF)

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.3782-3782

2021

Volltextzugriff (PDF)

Inhibitory Effect of Statins on Renal Epithelial-to-Mesenchymal Transition

American journal of nephrology, 2006, Vol.26 (4), p.381-387

2006

Volltextzugriff (PDF)

Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS8054-TPS8054

2021

Volltextzugriff (PDF)

Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients

Future oncology (London, England), 2022-11, Vol.18 (36), p.3983-3991

2022

Volltextzugriff (PDF)

Neural Refractory Properties and Behavioural Measures of Temporal Resolution and Speech Perception in Cochlear Implant Users

Patel, Sharmila

2021

Volltextzugriff (PDF)

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Expert opinion on investigational drugs, 2008-12, Vol.17 (12), p.1865-1882

2008

Volltextzugriff (PDF)

Initial surgical and clinical experience with the Nucleus CI532 slim modiolar electrode in the UK

Cochlear implants international, 2019-07, Vol.20 (4), p.207-216

2019

Volltextzugriff (PDF)

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

British journal of haematology, 2024-06, Vol.204 (6), p.2227-2232

2024

Volltextzugriff (PDF)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

British journal of haematology, 2022-11, Vol.199 (3), p.355-365

2022

Volltextzugriff (PDF)

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8011-8011

2022

Volltextzugriff (PDF)

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood, 2022-11, Vol.140 (Supplement 1), p.10144-10147

2022

Volltextzugriff (PDF)

1 – 25 von 141

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(141)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(57)
Humans
(44)
Female
(20)
Male
(19)
Adult
(16)
Aged
(16)
Middle Aged
(13)
Animals
(10)
Hematology
(9)
Multiple Myeloma
(9)
General & Internal Medicine
(8)
Medicine, General & Internal
(8)
Oncology
(8)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Biological And Medical Sciences
(7)
Gastroenterology And Hepatology
(7)
Lenalidomide - Therapeutic Use
(7)
Medical Sciences
(7)
Multiple Myeloma - Drug Therapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation

Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation

Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma

Characteristics and Outcomes of Non-Transplanted Patients with Newly Diagnosed Multiple Myeloma (NDMM) Initiating Treatment with Bortezomib, Lenalidomide, and Dexamethasone (VRd) As First-Line of Therapy

Inhibitory Effect of Statins on Renal Epithelial-to-Mesenchymal Transition

Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study

Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients

Neural Refractory Properties and Behavioural Measures of Temporal Resolution and Speech Perception in Cochlear Implant Users

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Initial surgical and clinical experience with the Nucleus CI532 slim modiolar electrode in the UK

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Suchergebnisse filtern